Method for inhibiting complement activation
OwnerRichard N. Pierson III, George L. Zorn III +3inventors
InventorsRichard N. Pierson III, George L. Zorn III, Todd D. Giorgio, Simon Robson, Agnes M. Azimzadeh
Life of this patent
Estimating the term…
Abstract
A method of inhibiting complement activation, particularly by a transplanted tissue, in a warm-blooded vertebrate. The method includes administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation by the transplanted tissue is inhibited. The platelet activity modulator can include a combination of a GPIb modulator and a GPIIb/GPIIIa modulator.
Claims34
A method of inhibiting complement activation in a warm-blooded vertebrate in which said inhibition is desired, the method comprising administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate, whereby complement activation is inhibited.
A method of inhibiting complement activation by a transplanted tissue in a warm-blooded vertebrate, the method comprising administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation by the transplanted tissue is inhibited.
A method of inhibiting rejection of a transplanted tissue in a warm-blooded vertebrate, the method comprising:
- administering a therapeutically effective amount of a GPIb modulator and a GPIIb/GPIIIa modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby rejection of the transplanted tissue is inhibited.
A method of enhancing tolerance of a xenograft transplant in a recipient, the method comprising:
- administering a therapeutically effective amount of a GPIb modulator and a GPIIb/GPIIIa modulator to a recipient before, during or after the recipient receives a xenograft transplant, whereby tolerance of the xenograft transplant is enhanced.
Dependencies are inferred from the claim text.